Showing 1,161 - 1,180 results of 1,447 for search '"liver disease"', query time: 0.07s Refine Results
  1. 1161

    The activity of a herbal medicinal product of Phyllanthus niruri and Silybum marianum powdered extracts (Heptex®) in patients with apparent risk factors for nonalcoholic steatohepa... by Mohamed Kamal Shaker, Mohamed Hassany, Basem Eysa, AbdulMoneim Adel, Ahmed Zidan, Shahnaz Mohamed

    Published 2025-01-01
    “…Abstract Background Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD) characterized by damage and inflammation of hepatocytes. …”
    Get full text
    Article
  2. 1162

    Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial Dysfunction by Thuy Linh Lai, So Young Park, Giang Nguyen, Phuc Thi Minh Pham, Seon Mee Kang, Jeana Hong, Jae-Ho Lee, Seung-Soon Im, Dae-Hee Choi, Eun-Hee Cho

    Published 2024-12-01
    “…Background Liver fibrosis is a common outcome of chronic liver disease and is primarily driven by hepatic stellate cell (HSC) activation. …”
    Get full text
    Article
  3. 1163

    Association between dietary betaine intake and overweight or obesity by Maierheba Kuerbanjiang, Wenzhuo Yu, Ting Shang, Yuchen Liu, Dina Muheyati, Mei-Xia Lv, Muhairemu Jielili, Jia Han

    Published 2024-12-01
    “…Abstract Betaine exhibits significant physiological functions in organisms and has positive impacts on obesity, alcohol-induced and metabolic-associated liver disease, diabetes, cardiovascular diseases, and certain cancers. …”
    Get full text
    Article
  4. 1164

    Apoptosis in the liver of male <em>db/db</em> mice during the development of obesity and type 2 diabetes by S. V. Michurina, I. Yu. Ishchenko, S. A. Arkhipov, M. A. Cherepanova, D. V. Vasendin, E. L. Zavjalov

    Published 2020-07-01
    “…Obesity and diabetes mellitus are known to lead to the development of metabolic syndrome and non-alcoholic fatty liver disease (NAFLD). The mechanisms of programmed cell death are actively involved in maintaining cellular homeostasis along development of NAFLD. …”
    Get full text
    Article
  5. 1165

    Protective Effects of Celastrol on Diabetic Liver Injury via TLR4/MyD88/NF-κB Signaling Pathway in Type 2 Diabetic Rats by Li-ping Han, Chun-jun Li, Bei Sun, Yun Xie, Yue Guan, Ze-jun Ma, Li-ming Chen

    Published 2016-01-01
    “…We firstly found that celastrol treatment could delay the progression of diabetic liver disease in type 2 diabetic rats via inhibition of TLR4/MyD88/NF-κB signaling cascade pathways and its downstream inflammatory effectors.…”
    Get full text
    Article
  6. 1166

    Single-cell transcriptomic analysis reveals characteristic feature of macrophage reprogramming in liver Mallory-Denk bodies pathogenesis by Zixuan Fang, Bei Zhong, Yi Shi, Wanmei Zhou, Maoping Huang, Samuel W. French, Xiaoping Tang, Hui Liu

    Published 2025-01-01
    “…Abstract Chronic liver diseases are highly linked with mitochondrial dysfunction and macrophage infiltration. …”
    Get full text
    Article
  7. 1167

    The causal relationship of cigarette smoking to metabolic disease risk and the possible mediating role of gut microbiota by Jingda Zhang, Lin Hou, Shanxiang Lei, Yan Li, Guogang Xu

    Published 2025-01-01
    “…Emerging evidence suggests that cigarette smoking contributes to a range of pathological metabolic injuries, including diabetes and nonalcoholic fatty liver disease (NAFLD). The impact of gut microbiota on metabolic health and diseases has been observed, but the causality remains uncertain. …”
    Get full text
    Article
  8. 1168

    Structural Disruption of Cilia and Increased Cytoplasmic Tubulin in Biliary Atresia—An Exploratory Study Focusing on Early Postoperative Prognosis Following Portoenterostomy by Patrícia Quelhas, Rui Oliveira, Carlos Kieling, Sandra Vieira, Jorge dos Santos

    Published 2025-01-01
    “…Liver samples from fourteen BA patients and six controls with another liver disease were analyzed by digital image analysis, with data evaluated using Spearman’s correlation and independent <i>t</i>-tests. …”
    Get full text
    Article
  9. 1169

    Association of triglyceride-glucose related indices with mortality among individuals with MASLD combined with prediabetes or diabetes by Yiheng Zhang, Juanli Wu, Tao Li, Yundong Qu, Yan Wang

    Published 2025-02-01
    “…Abstract Background The prognostic significance of triglyceride-glucose (TyG)-related indices in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) combined with prediabetes or diabetes is not yet fully understood. …”
    Get full text
    Article
  10. 1170

    The role of the interleukin family in liver fibrosis by Zixin Zhang, Zixin Zhang, Jiahui Wang, Hui Li, Qun Niu, Qun Niu, Yujing Tao, Yujing Tao, Xin Zhao, Xin Zhao, Zijian Zeng, Zijian Zeng, Haijian Dong, Haijian Dong

    Published 2025-02-01
    “…It is a critical step in the progression from chronic liver disease to cirrhosis and hepatocellular carcinoma. …”
    Get full text
    Article
  11. 1171
  12. 1172

    Prevalence of complications and comorbidities associated with obesity: a health insurance claims analysis by Jay P. Bae, David R. Nelson, Kristina S. Boye, Kieren J. Mather

    Published 2025-01-01
    “…Disorders such as obstructive sleep apnea, osteoarthritis, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, coronary heart diseases (CHD), and chronic kidney diseases also exhibited substantial burden among those with obesity. …”
    Get full text
    Article
  13. 1173

    Visfatin Induces Inflammation and Insulin Resistance via the NF-κB and STAT3 Signaling Pathways in Hepatocytes by Yu Jung Heo, Sung-E Choi, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Yup Kang, Kwan Woo Lee, Hae Jin Kim

    Published 2019-01-01
    “…Insulin resistance and inflammation are the principal pathogeneses of nonalcoholic fatty liver disease (NAFLD), but the relationship, if any, between visfatin and NAFLD remains unclear. …”
    Get full text
    Article
  14. 1174

    Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study by Ping Chen, Yang Zheng, Yubo Cai, Pengfei Zou, Nan Li, Conggao Peng, Hainv Gao, Jimin Liu, Yongping Chen, Zhaowei Tong, Lanjuan Li

    Published 2020-01-01
    “…Chronic HCV infection affects 80 million people globally and may progress to advanced liver disease. The present study aims to investigate the present epidemiology of HCV infection in a southeastern Chinese surgical patient cohort. …”
    Get full text
    Article
  15. 1175

    Development of novel nucleic acid therapy aimed at directly controlling liver fibrosis by Tomohiro Umezu, Masakatsu Takanashi, Koji Fujita, Akio Ishikawa, Yuichirou Harada, Yoshinari Matsumoto, Masahiko Kuroda, Yoshiki Murakami

    Published 2025-03-01
    “…In a mouse model of chronic liver disease treated with carbon tetrachloride (CCl4), the inhibitory effect on liver fibrosis was evaluated with oral administration of the modified nucleic acid. …”
    Get full text
    Article
  16. 1176

    Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases by Marilena Durazzo, Arianna Ferro, Victor Manuel Navarro-Tableros, Andrea Gaido, Paolo Fornengo, Fiorella Altruda, Renato Romagnoli, Søren K. Moestrup, Pier Luigi Calvo, Sharmila Fagoonee

    Published 2025-01-01
    “…In this review, we highlight the major molecular changes occurring in patients affected by metabolic dysfunction-associated steatotic liver disease, viral hepatitis (Delta virus), and autoimmune chronic liver diseases (autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis). …”
    Get full text
    Article
  17. 1177

    Subcutaneous Fat Obesity in a High Body Mass Index Donor Is Not a Contraindication to Living Donor Hepatectomy by Hirak Pahari, Amey Sonavane, Amruth Raj, Anup Kumar Agrawal, Ambreen Sawant, Deepak Kumar Gupta, Amit Gharat, Vikram Raut

    Published 2023-01-01
    “…A 39-year-old wife donated her right lobe of liver to her 43-year-old husband with nonalcoholic steatohepatitis-related chronic liver disease (CLD). His indications were refractory ascites, hepatic encephalopathy, acute kidney injury, recurrent elbow and urine infections leading to cachexia. …”
    Get full text
    Article
  18. 1178

    Metallothionein 1B attenuates inflammation and hepatic steatosis in MASH by inhibiting the AKT/PI3K pathway by Canghai Guan, Xinlei Zou, Wujiang Shi, Jianjun Gao, Chengru Yang, Yifei Ge, Zhaoqiang Xu, Shaowu Bi, Xiangyu Zhong

    Published 2025-01-01
    “…Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of metabolic dysfunction–associated fatty liver disease metabolic dysfunction-associated steatohepatitis , characterized by hepatic steatosis, inflammation, and fibrosis. …”
    Get full text
    Article
  19. 1179

    Cardiovascular Profile and Cardiovascular Imaging After Bariatric Surgery: A Narrative Review by Mihaela Toader, Liliana Gheorghe, Costin Chirica, Ionuț-Alexandru Ghicu, Sabina-Ioana Chirica, Andreea Isabela Mazga, Danisia Haba, Mădălina Maxim, Ancuța Andreea Miler, Daniela Crișu, Mihai Ștefan Cristian Haba, Daniel Vasile Timofte

    Published 2025-01-01
    “…<i>Materials and Methods</i>: The patients eligible for BaS commonly suffer from multiple chronic conditions, including type 2 diabetes, obstructive sleep apnea, cardiovascular diseases, and non-alcoholic fatty liver disease. Additionally, obesity contributes to an increased probability of developing certain types of cancer, osteoarthritis, urinary incontinence, and chronic kidney disease. …”
    Get full text
    Article
  20. 1180

    Markers of Inflammation and Fibrosis in Alcoholic Hepatitis and Viral Hepatitis C by Manuela G. Neuman, Hemda Schmilovitz-Weiss, Nir Hilzenrat, Marc Bourliere, Patrick Marcellin, Cristhian Trepo, Tony Mazulli, George Moussa, Ankit Patel, Asad A. Baig, Lawrence Cohen

    Published 2012-01-01
    “…High levels of profibrinogenic cytokine transforming factor beta (TGF-β), metalloprotease (MMP2), and tissue inhibitor of matrix metalloprotease 1 (TIMP1) contribute to fibrogenesis in hepatitis C virus (HCV) infection and in alcohol-induced liver disease (ALD). The aim of our study was to correlate noninvasive serum markers in ALD and HCV patients with various degrees of inflammation and fibrosis in their biopsies. …”
    Get full text
    Article